Pfizer, Novartis: CDC's MenB nod is too narrow

Pfizer ($PFE) and Novartis ($NVS) have snagged a nod from the CDC's Advisory Committee on Immunization Practices (ACIP) for their recently approved meningitis B vaccines. There's just one problem: It doesn't cover nearly as large a population as the pharma giants would like. Thursday, ACIP voted unanimously to recommend Pfizer's Trumenba and Novartis' Bexsero for use in so-called high-risk groups--namely individuals with immune deficiencies and those in close proximity to ongoing outbreaks. And while both vaccinemakers agree the verdict is a step in the right direction, it's not nearly as broad as their FDA approvals, which cover adults ages 10 to 25. More

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.